Pantop%252525252525252525252525252525252525252520ds

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by irreversibly binding to the H+/K+-ATPase enzyme system at the secretory surface of the gastric parietal cell. ## Primary Indications * Erosive esophagitis associated with GERD. * Maintenance of healing of erosive esophagitis. * Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). * Short-term treatment of GERD symptoms. ## Adult Dosing * **GERD/Erosive Esophagitis:** 40 mg orally or IV once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. * **Hypersecretory Conditions:** Starting dose is 40 mg twice daily. Doses up to 240 mg/day have been utilized; titration based on clinical response and acid output. * **IV Administration:** 40 mg IV once daily; transitions to oral therapy as soon as patient can tolerate it. ## Pediatric Dosing * **GERD (Age ≥5 years):** * 15 kg to <40 kg: 20 mg once daily for up to 8 weeks. * ≥40 kg: 40 mg once daily for up to 8 weeks. * *Note:* IV dosing in pediatric patients is not generally established for routine GERD management. ## Dose Adjustments * **Hepatic Impairment:** No initial dose adjustment is required, but clinical monitoring is advised in severe hepatic impairment (Child-Pugh C). * **Renal Impairment:** No dosage adjustment necessary. * **Geriatric:** Generally no dose adjustment required. ## Contraindications * Known hypersensitivity to pantoprazole or any substituted benzimidazole (e.g., omeprazole, lansoprazole). * Concurrent use with rilpivirine-containing products. ## Adverse Effects * **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence. * **Serious:** *Clostridioides difficile*-associated diarrhea, acute interstitial nephritis, vitamin B12 deficiency (long-term use), hypomagnesemia, and an increased risk of bone fractures (hip, wrist, spine) with high-dose/long-term therapy. ## Key Drug Interactions * **pH-Dependent Drugs:** May decrease absorption of drugs requiring acidic gastric pH (e.g., atazanavir, ketoconazole, iron salts, mycophenolate mofetil). * **Methotrexate:** PPIs may increase serum levels/toxicity of methotrexate, especially in high-dose therapy. * **Clopidogrel:** Potential reduced antiplatelet effect, though clinical significance remains debated. ## Monitoring * Monitor for signs of hypomagnesemia (e.g., tremors, arrhythmias) during long-term therapy. * Assess vitamin B12 status if used for >1 year. * Monitor for persistent diarrhea or signs of *C. difficile* infection. ## Clinical Pearls * **Administration:** Tablets should be swallowed whole; do not crush or chew. IV administration should be a 15-minute infusion or a 2-minute slow bolus (per institutional protocol). * **De-prescribing:** Always evaluate the necessity of PPI therapy; many patients are placed on PPIs without a valid long-term indication. * **Consistency:** Take orally 30–60 minutes before a meal for optimal acid control. *** **Disclaimer:** This information is for educational purposes for healthcare professionals. Dosing may vary based on local protocols, institutional guidelines, or specific patient comorbidities. Always verify current prescribing information via the official FDA-approved package insert or recognized clinical drug databases before prescribing or administering medication.